41 results about "Serum insulin level" patented technology

Methods are provided for reducing serum proinsulin levels, lessening post-prandial pancreatic stress, and reducing risk factors for atherosclerosis in subjects with diabetes mellitus, type 2. The method includes administration of insulin in a manner that mimics the meal-related first phase insulin response, using a dose sufficient to reduce serum levels of proinsulin. In some embodiments of the method insulin administration is commenced early in the course of the disease. Mimicking first phase kinetics, peak serum insulin levels can be reached within about 18 minutes of administration. In increasingly preferred embodiments peak serum insulin levels can be reached within about 15, 12, or 10 minutes of administration. Serum insulin levels return to baseline within about two hours of administration.

The invention is directed to a dietary supplement which contains mannoheptulose. Mannoheptulose occurs naturally in avocado fruit. The dietary supplement and its method of use can lower serum insulin levels and lower a subject's weight. The dietary supplement in its disclosed form includes a controlled release system for mannoheptulose. The dietary supplement may also include one or more amino acids.

Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and / or administering to the patient an effective amount of an agent which reduces serum insulin levels.

The invention is directed to a dietary supplement which contains mannoheptulose. Mannoheptulose occurs naturally in avocado fruit. The dietary supplement and its method of use can lower serum insulin levels and lower a subject's weight. The dietary supplement in its disclosed form includes a controlled release system for mannoheptulose. The dietary supplement may also include one or more amino acids.

The invention is directed to a dietary supplement which contains mannoheptulose. Mannoheptulose occurs naturally in avocado fruit. The dietary supplement and its method of use can lower serum insulin levels and lower a subject's weight. The dietary supplement in its disclosed form includes a controlled release system for mannoheptulose. The dietary supplement may also include one or more amino acids.

The invention discloses a new medical application of loganin, and in particular relates to an application of the loganin in preparation of medicaments for treating diabetes, wherein the loganin is extracted from dogwood. The method for extracting the loganin comprises the following steps of: (1) performing water extraction and alcohol precipitation on dogwood coarse powder to obtain a dogwood water extraction and alcohol precipitation extracting solution; (2) loading the dogwood water extraction and alcohol precipitation extracting solution into a macroporous adsorption resin column, and performing enrichment to obtain dogwood iridoid glycosides; (3) performing chromatographic separation by using a silica gel column to obtain a loganin flow component; and (4) purifying to obtain a loganin monomeric compound. Pharmacodynamics experimental results prove that the loganin has the functions of reducing the content of blood sugar, serum AGEs and urokinase protein, raising the serum insulin level, relieving pathologic lesions of pancreas, kidney, liver, heart, testis and the like, and obviously improving a 'three more one less' symptom. Therefore, the loganin can be used for preparing the medicaments for treating the diabetes.

The invention discloses bifidobacterium pseudocatenulatum CCFM1046, a composition, a fermented food, applications, a microbial inoculum and a preparation method thereof. As the bifidobacterium pseudocatenulatum CCFM1046 can tolerate gastrointestinal environments in human bodies, the rising of hepatic triglyceride content of metabolic syndrome mice caused by high-fat diet can be significantly improved; the weight increasing of the metabolic syndrome mice can be alleviated; the abnormal fasting blood glucose and oral glucose tolerance of the metabolic syndrome mice can be significantly improvedas well; area under the curve of glucose tolerance can be reduced; serum insulin levels can be enhanced; the rising of low-density lipoprotein cholesterol in serum of the metabolic syndrome mice caused by the high-fat diet can be significantly improved; and the rising of Proteus genus in intestinal tracts caused by the high-fat diet can also be significantly improved. The bifidobacterium pseudocatenulatum CCFM1046 can be used for preparing the pharmaceutical composition and fermented food for alleviating metabolic syndromes and decreasing the occurrence of Parkinson, intestinal infection, urinary tract and kidney infection and other diseases, so that the bifidobacterium pseudocatenulatum CCFM1046 can have very wide application prospects.

The invention discloses a Plantain seed extract and application thereof. The Plantain seed extract is acquired by reflux extraction of Plantain seed with 2-6 volume times of 60-90vol% ethanol aqueous solution 2-6 times. The Plantain seed extract contains acteoside, isoacteoside, geniposidic acid, ferulic acid, and Cheqiansu A and Cheqiansu B. In-vivo experiments show that the Plantain seed extract provided by the invention can promote glucose consumption and has lower toxicity to cells; and simultaneously in-vitro experiments show that the Plantain seed extract can significantly increase serum insulin level and reduce fasting blood-glucose level, presents good medicinal value in treatment of diabetes; therefore, the Plantain seed extract can be used in the preparation of pharmaceutical medicaments for treating diabetes singly or together with a pharmaceutically acceptable composition composed of a drug carrier.

The invention discloses bifidobacterium pseudocatenulatum CCFM1047, a composition, fermented food, application and bacterial agent of the bifidobacterium pseudocatenulatum CCFM1047 and a preparation method of the bacterial agent of the bifidobacterium pseudocatenulatum CCFM1047. The bifidobacterium pseudocatenulatum CCFM1047 can tolerate the gastrointestinal environment of the human body, significantly improve abnormal fasting blood glucose and abnormal oral glucose tolerance of a mouse with the metabolic syndrome, reduce the area under the drug-time curve of glucose tolerance, reduce the serum insulin level, significantly relieve the weight rise of the mouse, significantly relieve the rise, caused by the high fat diet, of content of low density lipoprotein cholesterol in serum and triglyceride in the liver of the mouse with the metabolic syndrome and significantly relieve the rise, caused by the high fat diet, of Proteus in the intestinal tract; the bifidobacterium pseudocatenulatum CCFM1047 is used for preparing the medicine composition and the fermented food which relieve the metabolic syndrome and reduce the occurrence of diseases such as the Parkinson disease, intestinal infection and urinary tract and kidney infection and has a quite wide application prospect.

The invention discloses bifidobacterium pseudocatenulatum CCFM1045, a composition, a fermented food, applications, a microbial inoculum and a preparation method thereof. As the bifidobacterium pseudocatenulatum CCFM1045 can tolerate gastrointestinal environments in human bodies, the abnormity of metabolic syndrome mouse serum liver function indexes ALT and AST caused by high-fat diet can be significantly improved; the abnormal oral glucose tolerance of metabolic syndrome mice can be significantly improved as well; area under the curve of glucose tolerance can be reduced; serum insulin levels can be decreased; the rising of triglycerides and total cholesterol content in serum of the metabolic syndrome mice caused by the high-fat diet can be significantly improved; and the rising of Proteusgenus in intestinal tracts caused by the high-fat diet can also be significantly improved. The bifidobacterium pseudocatenulatum CCFM1045 can be used for preparing the pharmaceutical composition and fermented food for alleviating metabolic syndromes and decreasing the occurrence of Parkinson, intestinal infection, urinary tract and kidney infection and other diseases, so that the bifidobacterium pseudocatenulatum CCFM1045 can have very wide application prospects.

The invention discloses a novel compound formed by the chemical coupling of a diphenylethlene compound and derivatives thereof as well as thiazolidine or oxazolidine midbody and a preparation method thereof. The invention also discloses a plurality of pharmaceutical applications of the compounds: reducing blood sugar, serum insulin level and triglycercide level of a diabete II animal model, treating diseases related to the insulin tolerance, such as polycystic ovary syndrome, hyperlipemia, coronary disease and ambient vascular diseases, and also treating inflammations and immunological diseases, especially diseases mediated by cytokines and cyclooxygenase cox, such as THF-Alpha, IL-1, IL-6 and / or COX-2.

The present invention relates to diabetes treating Chinese medicine, and aims at providing one kind of Chinese medicine with reasonable recipe and the functions of lowering blood sugar level, reducing blood fat, lowering blood viscosity, lowering peripheral serum insulin level and remitting diabetes complication. The recipe for the medicine consists of mulberry leaf 26-29 wt%, lotus leaf 16-48 wt% and red sage 25-42 wt%. By means of clearing away wetness and heat, lifting clearness and promoting blood circulation to disperse blood clots, the medicine can promote insulin secretion, promote metabolism, control weight, reduce blood sugar and blood fat, lower blood viscosity and promote microcirculation to treat diabetes and its complication.

The invention relates to a novel application of niclosamide ethanolamine salt, and in particular to the application of the niclosamide ethanolamine salt in preparing medicines for preventing and treating diabetes type 1 and complications thereof; and the invention also conducts studies on the protective effect and the action mechanism of the niclosamide ethanolamine salt on the diabetes type 1 and the complications thereof. Results show that the niclosamide ethanolamine salt can improve symptoms of polyuria, polydipsia and polyphagia in a mouse with the diabetes type 1, reduce blood glucose, glycosylated hemoglobin and urine glucose levels, increase a serum insulin level and improve pancreas pathological damage. In the aspect of protecting a kidney target organ, the niclosamide ethanolamine salt can reduce a urinary albumin excretion rate, lower a creatinine clearance rate, diminish the area of glomerular vascular loops, reduce NAG and NGAL discharge in urine and inhibit activation of Akt / mTOR / 4E-BP1 signaling pathways in kidney tissues. In addition, the niclosamide ethanolamine salt can also take an obvious protecting effect on liver and achieve a significant improving effect on muscle functions. Therefore, the niclosamide ethanolamine salt has a significant protective effect on the diabetes type 1 and the complications thereof.

The invention discloses a use of lentinan in preparation of a drug for preventing diabetes type 1. The invention discloses a use of lentinan in preparation of a drug for adjuvant treatment on diabetes type 1. Lentinan is injected into the abdominal cavity of an NOD mouse with spontaneous diabetes type 1 and influence produced by lentinan with body immunity adjustment functions on NOD mouse diabetes incidence is observed. Lentinan reduces NOD mouse insulitis incidence through improving CD25, Foxp3 and T cell (Treg) quantity in NOD mouse spleen, pancreas and lymph nodes, inhibiting CD3, CD8 and cytotoxic T cell (CTL) activation and reducing proinflammatory cytokine secretion, improves a serum insulin level, keeps a blood sugar normal level, finally reduces NOD mouse diabetes type 1 incidence and improves an NOD mouse survival rate.

Methods are provided for reducing serum proinsulin levels, lessening post-prandial pancreatic stress, and reducing risk factors for atherosclerosis in subjects with diabetes mellitus, type 2. The method includes administration of insulin in a manner that mimics the meal-related first phase insulin response, using a dose sufficient to reduce serum levels of proinsulin. In some embodiments of the method insulin administration is commenced early in the course of the disease. Mimicking first phase kinetics, peak serum insulin levels can be reached within about 18 minutes of administration. In increasingly preferred embodiments peak serum insulin levels can be reached within about 15, 12, or 10 minutes of administration. Serum insulin levels return to baseline within about two hours of administration.

The invention relates to a drug which is used for treating coronary heart disease, has the functions of activating blood circulation to dissipate blood stasis and regulating qi to alleviate pain, and is applicable to dilating coronary vessel and increasing blood flow. The drug is characterized by being made from active components such as notoginseng, red peony root, finger citron, alisma orientale, licorice and the like by finish processing, and realizes 'multi-target treatment' during the treatment process due to reasonable purification while keeping the original active components to not be changed; the drug can promote regeneration of the capillary vessel in myocardium, increase the blood flow of coronary artery branch or collateral circulation, and restore blood supply of the myocardium; the drug has the functions of lowering cholesterol, triglyceride and low-density lipoprotein and increasing high density lipoprotein, and can adjust lipid metabolism, slow down occurrence and development of the coronary heart disease according to important causes of the coronary heart disease (hyperlipemia, abnormal metabolism of the lipid and the like); and the drug further has effects on reducing ventricular dilatation degree, inhibiting left ventricular remodeling after myocardial infarction, improving serum insulin level and improving insulin resistance and the like.

The invention discloses bifidobacterium pseudocatenulatum CCFM1048, a composition, fermented food, application and bacterial agent of the bifidobacterium pseudocatenulatum CCFM1048 and a preparation method of the bacterial agent of the bifidobacterium pseudocatenulatum CCFM1048. The bifidobacterium pseudocatenulatum CCFM1048 can tolerate the gastrointestinal environment of the human body, significantly relieve the rise, caused by the high fat diet, of content of triglyceride in the liver of a mouse with the metabolic syndrome, relieve the weight rise of the mouse with the metabolic syndrome, significantly improve abnormal fasting blood glucose and abnormal oral glucose tolerance of the mouse with the metabolic syndrome, reduce the area under the drug-time curve of glucose tolerance, improve the serum insulin level, significantly relieve the rise, caused by the high fat diet, of content of low density lipoprotein cholesterol in serum and significantly relieve the rise, caused by the high fat diet, of Proteus in the intestinal tract; the bifidobacterium pseudocatenulatum CCFM1048 is used for preparing the medicine composition and the fermented food which relieve the metabolic syndrome and reduce the occurrence of diseases such as the Parkinson disease, intestinal infection and urinary tract and kidney infection and has a quite wide application prospect.

Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and / or administering to the patient an effective amount of an agent which reduces serum insulin levels.

A method of controlling serum insulin levels in an individual is disclosed. The method comprises the step of administering to the individual a food composition comprising heat and moisture treated starch (HMT starch).

The invention provides an application of an isodaphnetin compound in the preparation of antidiabetic medicines. The structural formula of isodaphnetin is shown in the specification. According to the invention, a high-sugar high-fat forage combined with a small dosage of streptozotocin (STZ) is applied to establish type 2 diabetes rat models, and male SD adult rats can be fed with the high-sugar high-fat forage for 1 month to induce insulin resistances and injected with a small dosage of the STZ 25mg each kilogram in an abdominal cavity mode to establish the type 2 diabetes rat models; and said given medicine is injected in the abdominal cavity mode, and blood sugar, serum insulin, glucagon, mental states, body weights, water drinking amounts, appetites and the like of the rates are detection indexes. Experiment results show that after treating with isodaphnetin, the blood sugar values and the serum insulin levels of the type 2 diabetes rat models are obviously decreased (P is less than 0.01), and there are no obvious blood sugar value differences among rats having obvious increased insulin levels (P is greater than 0.05). So, isodaphnetin can be used for preparing the antidiabetic medicines. The medicine is a medicinal composition comprising isodaphnetin as an active compound and a medicinal carrier.

The invention discloses a carboxymethylated lachnum extracellular polysaccharide prepared by modifying a lachnum YM216 extracellular polysaccharide with the strain preservation number of CCTCC (China Center For Type Culture Collection) M 2016603, and application of the carboxymethylated lachnum extracellular polysaccharide to a hypoglycemic drug. A pharmacodynamics test shows that the carboxymethylated lachnum extracellular polysaccharide can be used for remarkably improving the glucose tolerance and body weight of type II diabetic mice induced by high-fat feed and streptozotocin and lowering glycosylated hemoglobin, fasting plasma glucose levels and serum insulin levels, and has a good blood glucose lowering function; furthermore, the carboxymethylated lachnum extracellular polysaccharide can be used for up-regulating the expression of glucokinase and adenosine monophosphate-activated protein kinase and down-regulating the expression of 6-phosphatase. By adopting the method disclosed by the invention, the blood glucose lowering activity of an original lachnum extracellular polysaccharide can be improved; the carboxymethylated lachnum extracellular polysaccharide has no toxic side effect and has positive meanings on an application range of the polysaccharide.

The invention relates to application of ZNRF3 / RNF43 in preparation of a medicine for regulating energy metabolism. It proves that the ZNRF3 / RNF43 double knockout can reduce the blood sugar content andserum insulin level, increase the sensitivity of the body to glucose and down-regulate the expression of glucose allogeneic related genes; meanwhile, liver lipid deposition is reduced, lipid synthesis and expression of inflammation-related genes are reduced, it is shown that the ZNRF3 / RNF43 double knockout can improve liver insulin resistance possibly through the ways of influencing glycoxenesis,lipid synthesis and the like, and then a theoretical basis is provided for preparing energy metabolism regulating medicine.

The invention discloses Bifidobacterium pseudosmallis CCFM1048, its composition, fermented food, application, bacterial agent and preparation method thereof. The Bifidobacterium pseudoserinus CCFM1048 can tolerate human gastrointestinal environment and significantly improve high-fat diet The resulting increase in liver triglyceride content in mice with metabolic syndrome; alleviated weight gain in mice with metabolic syndrome; significantly improved fasting blood glucose and abnormal oral glucose tolerance in mice with metabolic syndrome, and reduced the area under the curve of glucose tolerance drugs. Improve serum insulin levels; significantly improve serum low-density lipoprotein cholesterol levels in mice with metabolic syndrome caused by high-fat diets; significantly improve the increase in intestinal Proteus species caused by high-fat diets, CCFM1048 is used to prepare and relieve metabolism Syndrome, reducing Parkinson's disease, intestinal infection, urinary tract, kidney infection and other diseases, the pharmaceutical composition and fermented food have a very wide application prospect.

The present invention discloses bifidobacterium pseudosmall chain CCFM1047, its composition, fermented food, application, bacterial agent and preparation method thereof. Bifidobacterium pseudosmall chain CCFM1047 can tolerate human gastrointestinal environment and significantly improve metabolic syndrome Fasting blood glucose and oral glucose tolerance in mice, reduce the area under the curve of glucose tolerance drugs, reduce serum insulin levels; significantly alleviate the weight gain of mice; significantly improve the low density of serum in mice with metabolic syndrome caused by high-fat diet Elevated lipoprotein cholesterol and liver triglyceride content; significantly alleviated the increase of Proteus genus in the intestine caused by high-fat diet, pseudosmall chain Bifidobacterium CCFM1047 was used to prepare and relieve metabolic syndrome, reduce Parkinson's, intestinal infection and The pharmaceutical composition and fermented food for urinary tract, kidney infection and other diseases have very broad application prospects.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating type II diabetes mellitus and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from ginsenoside, rhizoma atractylodis macrocephalae, radix rehmanniae, radix astragali, rhizoma dioscoreae, rhizoma phragmitis, radix ophiopogonis, fructus schisandrae, fructus lycii, rhizoma alismatis, poria cocos, radix puerariae, rhizoma anemarrhenae and fructus corni. The traditional Chinese medicine composition has the effects of tonifying qi and yin, tonifying the spleen and kidney, clearing heat for promoting salivation, and promoting blood circulation to remove blood stasis. Pharmacodynamic researches show that after the traditional Chinese medicine composition intervenes in a type II diabetic db / db mouse, the basic blood glucose value of the mouse can be remarkably reduced, the phenomena of polydipsia and polyphagia are improved, the glucose tolerance is improved, the serum insulin level, the glycosylated hemoglobin level and the total cholesterol level are reduced, and the curative effect is not remarkably different from that of an independent clinical medicine. Therefore, the traditional Chinese medicine composition can be used as the clinical independent medicine and has value of treating the type II diabetes mellitus.

The invention discloses a miR-29 sponge, and further provides a nucleic acid construct containing the same. The invention finds that the miR-29 sponge can adsorb miR-29a-3p and miR-29b-3p in the body,close the functions of the miR-29a-3p and the miR-29b-3p and inhibit secretion of pro-inflammatory cytokines, so that insulitis of NOD mice is relieved, the serum insulin level is increased, the blood glucose tends to be normal, and finally, the onset of Type 1 diabetes mellitus (T1DM) of NOD (non-obese diabetic) mice is remarkably reduced, and the survival rate of the NOD mice is increased.

This invention provides a medicine Ketangwan capable of inducing the synthesis of insulin and it's preparation method. Said medicine comprises Jobs tcars, golden cypress and pacomia lactiflora pall and is prepared through grinding fried golden cypress, fried radix paconiae alba and fried pig's kidney; decocting and concentrating Jobs tcars and extracting by using alcohol, adding with said ground powder of golden cypress, radix paconiac alba and pig's kidney, then stirring, baking and grinding to make coated pills.

The invention relates to a novel application of niclosamide ethanolamine salt, and in particular to the application of the niclosamide ethanolamine salt in preparing medicines for preventing and treating diabetes type 1 and complications thereof; and the invention also conducts studies on the protective effect and the action mechanism of the niclosamide ethanolamine salt on the diabetes type 1 and the complications thereof. Results show that the niclosamide ethanolamine salt can improve symptoms of polyuria, polydipsia and polyphagia in a mouse with the diabetes type 1, reduce blood glucose, glycosylated hemoglobin and urine glucose levels, increase a serum insulin level and improve pancreas pathological damage. In the aspect of protecting a kidney target organ, the niclosamide ethanolamine salt can reduce a urinary albumin excretion rate, lower a creatinine clearance rate, diminish the area of glomerular vascular loops, reduce NAG and NGAL discharge in urine and inhibit activation of Akt / mTOR / 4E-BP1 signaling pathways in kidney tissues. In addition, the niclosamide ethanolamine salt can also take an obvious protecting effect on liver and achieve a significant improving effect on muscle functions. Therefore, the niclosamide ethanolamine salt has a significant protective effect on the diabetes type 1 and the complications thereof.

The invention discloses a miR-29 sponge, and further provides a nucleic acid construct comprising the miR-29 sponge. The present invention finds that the miR-29 sponge can absorb miR-29a-3p and miR-29b-3p in the body and close its function, inhibit the secretion of pro-inflammatory cytokines, thereby alleviating the occurrence of insulitis in NOD mice, increasing serum insulin levels, maintaining The blood sugar tends to normal level, finally significantly reduces the incidence of type 1 diabetes in NOD mice, and improves the survival rate of NOD mice.